Kairos Pharma (NYSE: KAPA) unveils investor update at 2026 LD Micro event

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Kairos Pharma, Ltd. furnished an investor presentation in connection with its appearance at the 2026 LD Micro Invitational XVI in Los Angeles. The presentation, available on the company’s website, is intended to update investors on its clinical program and partnering activities.

The materials are furnished, not filed, under Item 8.01 of the Exchange Act and attached as Exhibit 99.1, meaning they are not subject to Section 18 liability or automatically incorporated into other securities law filings.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

LD Micro Invitational dates: May 18–19, 2026 Exhibit 99.1: Investor Presentation Exhibit 104: Cover Page Inline XBRL

3 metrics

LD Micro Invitational dates May 18–19, 2026 Event in Los Angeles where the presentation is given

Exhibit 99.1 Investor Presentation Furnished under Item 8.01 of the Exchange Act

Exhibit 104 Cover Page Inline XBRL Interactive data file with embedded XBRL tags

Key Terms

Emerging growth company, Investor Presentation, LD Micro Invitational XVI, Inline XBRL

4 terms

Emerging growth company regulatory

"Emerging growth company Item 8.01. Other Events."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Investor Presentation financial

"issued a new investor presentation, which will be published"

An investor presentation is a carefully prepared talk or visual display that explains a company's business, goals, and financial performance. It helps investors understand how the company operates and its future prospects, much like a report card or progress update. These presentations are important because they provide transparency and help investors decide whether to support or invest in the company.

LD Micro Invitational XVI financial

"presented today at the 2026 LD Micro Invitational XVI"

Inline XBRL technical

"Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

Understanding 8-K Material Events →

05/18/2026 - 08:31 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 18, 2026

Kairos Pharma, Ltd.

(Exact name of registrant as specified in its charter)

Delaware

001-42275

46-2993314

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2355 Westwood Blvd., #139

Los Angeles CA 90064

(Address of principal executive offices) (Zip Code)

(310) 948-2356

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol (s)		Name of each exchange on which registered
Common Stock, par value $0.001, per share		KAPA		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On May 18, 2026, Kairos Pharma, Ltd., a Delaware corporation (the “Company”), issued a new investor presentation, which will be published on the Company’s website, www.kairospharma.com, and presented today at the 2026 LD Micro Invitational XVI (the “LD Micro Invitational”), set to take place in Los Angeles, CA May 18-19, 2026. As part of its participation in the LD Micro Invitational, the Company’s Chief Executive Officer, John Yu, will present the investor presentation to provide an update on the Company’s clinical program and partnering activities.

A copy of the investor presentation is being furnished as Exhibit 99.1 to this Form 8-K. The information included in this Item 8.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filings.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description of Document
99.1		Investor Presentation
104		Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 18, 2026	KAIROS PHARMA, LTD.

	By:	/s/ John S. Yu
		John S. Yu
		Chief Executive Officer

Exhibit 99.1

Source: View Original Filing on SEC EDGAR

FAQ

What did Kairos Pharma (KAPA) disclose in its latest 8-K filing?

Kairos Pharma disclosed that it furnished a new investor presentation as Exhibit 99.1. The presentation will be posted on its website and used at the 2026 LD Micro Invitational XVI to update investors on clinical and partnering activities.

What is the purpose of Kairos Pharma’s new investor presentation for KAPA shareholders?

The investor presentation is meant to provide an update on Kairos Pharma’s clinical program and partnering activities. It supports the company’s appearance at the 2026 LD Micro Invitational XVI and will be accessible on the company’s website for interested investors.

Where will Kairos Pharma (KAPA) present its investor materials mentioned in the 8-K?

Kairos Pharma will present the investor materials at the 2026 LD Micro Invitational XVI in Los Angeles, California. The event is scheduled for May 18–19, 2026, and the company’s CEO, John Yu, will present the update to attendees.

How is the Kairos Pharma (KAPA) investor presentation treated under U.S. securities laws?

The investor presentation is furnished, not filed, under Item 8.01 of the Exchange Act. As furnished information, it is not subject to Section 18 liability and is not automatically incorporated into other Securities Act or Exchange Act filings.

Who will present Kairos Pharma’s (KAPA) investor update at the LD Micro Invitational?

Kairos Pharma’s Chief Executive Officer, John Yu, will present the investor update. He will use the new investor presentation to brief participants at the 2026 LD Micro Invitational XVI on the company’s clinical program and partnering efforts.

Filing Exhibits & Attachments

36 documents